News

Filter

Current filters:

None

8151 to 8160 of 96179 results

Immuron joins academia for C. Difficile therapeutics

31-01-2012

Australian biotechnology firm Immuron (ASX: IMC) has entered into a collaboration agreement with Australia’s…

Antibiotics and Infectious diseasesAsia-PacificBiotechnologyImmuronResearch

New hope for amyloidosis patients facing organ transplants

31-01-2012

Amyloidosis patients are expected to see some significant breakthroughs in treatment over the next three…

BiotechnologyMarkets & MarketingPharmaceuticalRare diseasesResearch

PhRMA transitions management of BRAT framework to CIRS

31-01-2012

The Pharmaceutical Research and Manufacturers of America (PhRMA) says it has transferred its Benefit-Risk…

North AmericaPharmaceuticalRegulationResearch

Faster-than-expected FDA approval of Roche’s vismodegib

31-01-2012

There was good news for Swiss drug major Roche's (ROG: SIX)subsidiary Genentech yesterday, when it received…

BiotechnologyCurisErivedgeGenentechNorth AmericaOncologyPharmaceuticalRegulationRochevismodegib

New Actavis/Bioton alliance aims to shake up diabetes market

31-01-2012

Icelandic generics drugmaker Actavis and Poland’s Bioton (WSE: BIO) have formed a joint venture…

ActavisBiotonDiabetesGenericsMarkets & MarketingMergers & AcquisitionsPharmaceutical

Research-based pharma pledges on neglected tropical diseases

31-01-2012

The research-based pharmaceutical industry has announced donations of 14 billion treatments this decade…

FinancialGlobalPharmaceuticalResearchTropical diseases

Shionogi sets up new EU unit; posts 37% profit hike

31-01-2012

Japanese drug major Shionogi (TYO: 4507) yesterday revealed that it has decided to establish its 100%…

Asia-PacificEuropeFinancialPharmaceuticalResearchShionogi

Cell Therapeutics updates on Pixuvri

30-01-2012

Seattle, USA-based Cell Therapeutics (Nasdaq and MTA: CTIC) says that it has voluntarily withdrawn its…

BiotechnologyCell TherapeuticsNorth AmericaOncologyPixuvriRegulation

8151 to 8160 of 96179 results

Back to top